New Delhi: Approximately 1,000 human volunteers are participating in clinical trials for each of the two indigenous Covid-19 vaccines in India, Dr. Balram Bhargava, Director General of Indian Council of Medical Research (ICMR) said while addressing a press conference on Tuesday.
Indigenously developed Bharat Biotech's COVAXIN and another candidate developed by Ahmedabad-based Zydus Cadila Healthcare Ltd have both received nods from Drugs Controller General of India (DCGI) for human clinical trials.
"Two Indian indigenous vaccine candidates have successfully completed pre-clinical trials. The results were submitted to the Drug Controller General of India, which gave approval to conduct clinical human trials," said Balram.
Affirming that India is perceived as an important vaccine supplier in the world, he said, "So, any vaccine candidate which is produced or developed in any part of the world will ultimately have to be sealed up by India or by China."
More than 150 vaccine candidates from 12 countries, including India, are in the race to counter the deadly virus that has infected over 1.2 crore people and killed more than 5.5 lakh worldwide in a little over six months.
"Russia has fast-tracked a vaccine which has been successful in its early phases. They have fast-tracked its development," said Bhargava amid reports that the Russian vaccine, deemed as the world's first Coronavirus vaccine is set to launch in mid-August.
Speaking at the press briefing, Balram also mentioned the success of China in speeding up the process of its Covid-19 vaccine programme and studies with that vaccine in the country. Apart from that, ICMR DG spoke about the speedy progress of the vaccine candidates in United States and the United Kingdom.
"The US has fast-tracked two of its vaccine candidates. The UK is also looking at how it can fast track the Oxford vaccine candidate, how it can fast track it for human use," added Balram.
On a question whether Covid-19 is airborne, Balram said, "There has been hypothesis and suggestions by several scientists that there may be some airborne transmission with microdroplets (less than 5 microns in size)...What remains important is physical distancing and use of masks."